Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Novo-Helisen Depot house dust mites
- Development stage
- Phase 2
- Lead developer
- Allergopharma
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
Novo-Helisen Depot house dust mites is an approved subcutaneous allergen immunotherapy (SCIT) product developed by Allergopharma. It consists of a native, aluminum hydroxide-adsorbed extract of house dust mites, specifically a 50/50 mixture of *Dermatophagoides pteronyssinus* and *Dermatophagoides farinae*. The therapy is indicated for the treatment of allergic rhinitis, allergic rhinoconjunctivitis, and allergic (bronchial) asthma triggered by house dust mite allergens in adults and adolescents. It works by modulating the immune system's response to these allergens, shifting the balance from a Th2-mediated allergic response toward a more tolerant immune profile (Th1/Treg), thereby reducing symptoms and the need for symptomatic medication. A simplified 'One Strength' up-dosing scheme is approved for this product, allowing for a faster escalation phase.
- Brand names
- Novo-Helisen DepotNovo-Helisen
- Other names
- Dermatophagoides pteronyssinus / Dermatophagoides farinae 50%/50% allergen extracthouse dust mite allergen extract
02
Targets
House dust mite allergen proteinIgE (Immunoglobulin E)
Beyond the preview
Go deeper on Novo-Helisen Depot house dust mites.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Novo-Helisen Depot house dust mites.